Difference between revisions of "Team:Duke/HP/Silver"
| Line 6: | Line 6: | ||
<h1>Patent Law </h1> | <h1>Patent Law </h1> | ||
<p>To brainstorm a path for the marketability of Duke IGEM’s invention, we looked at the potential patentability of genetically-modified bacteria capable of Taxol production. This is an essential step, because the ability to earn future funding and to incentivize a pharmaceutical manufacturer to use our product in the market is contingent upon the company having an exclusive right to the invention. Having argued a case for why IGEM’s invention is patentable, the next step should be to work with Duke University patent attorneys to get the application and licensing processes started. </p> | <p>To brainstorm a path for the marketability of Duke IGEM’s invention, we looked at the potential patentability of genetically-modified bacteria capable of Taxol production. This is an essential step, because the ability to earn future funding and to incentivize a pharmaceutical manufacturer to use our product in the market is contingent upon the company having an exclusive right to the invention. Having argued a case for why IGEM’s invention is patentable, the next step should be to work with Duke University patent attorneys to get the application and licensing processes started. </p> | ||
| + | <br> | ||
| + | <a href="https://static.igem.org/mediawiki/2016/3/37/T--Duke--Patent_Law.pdf">An Overview and Analysis of the Societal Impacts of Taxol Biosynthesis in the United States</a> | ||
| + | <br> | ||
| + | <br> | ||
| + | |||
| + | <center><embed src="https://static.igem.org/mediawiki/2016/3/37/T--Duke--Patent_Law.pdf" width="900" height="1120" type='application/pdf'></center> | ||
| + | |||
</div> | </div> | ||
</html> | </html> | ||
Latest revision as of 23:55, 19 October 2016
Patent Law
To brainstorm a path for the marketability of Duke IGEM’s invention, we looked at the potential patentability of genetically-modified bacteria capable of Taxol production. This is an essential step, because the ability to earn future funding and to incentivize a pharmaceutical manufacturer to use our product in the market is contingent upon the company having an exclusive right to the invention. Having argued a case for why IGEM’s invention is patentable, the next step should be to work with Duke University patent attorneys to get the application and licensing processes started.
An Overview and Analysis of the Societal Impacts of Taxol Biosynthesis in the United States
